| Literature DB >> 34794321 |
Wugong Qu1, Shuanbao Yu1, Jin Tao1, Biao Dong1, Yafeng Fan1, Haopeng Du1, Haotian Deng1, Junxiao Liu1, Xuepei Zhang1.
Abstract
PURPOSE: To evaluate the incidence and locations of positive surgical margin (PSM) among Chinese men undergoing RARP and identify the preoperative predictors for PSM.Entities:
Keywords: positive surgical margin; prostate cancer; radical prostatectomy; robot
Mesh:
Year: 2021 PMID: 34794321 PMCID: PMC8645302 DOI: 10.1177/10732748211055265
Source DB: PubMed Journal: Cancer Control ISSN: 1073-2748 Impact factor: 3.302
Comparison of Clinical Parameters by Status of Surgical Margin Following Robot-Assisted Radical Prostatectomy.
| Parameter | Overall (n = 393) | Surgical Margin Status | ||
|---|---|---|---|---|
| Negative (n = 260) | Positive (n = 133) | |||
| Age (years) | 67 (63–72) | 67 (63–72) | 68 (63–73) | .993 |
| Smoking history (n, %) | .841 | |||
| No | 270 (69) | 180 (69) | 90 (68) | |
| Yes | 123 (31) | 80 (31) | 43 (32) | |
| Drinking history (n, %) | .683 | |||
| No | 322 (82) | 215 (83) | 107 (80) | |
| Yes | 71 (18) | 45 (17) | 26 (20) | |
| Hypertension (n, %) | .341 | |||
| No | 265 (67) | 180 (69) | 85 (64) | |
| Yes | 128 (33) | 80 (31) | 48 (36) | |
| Diabetes mellitus (n, %) | .225 | |||
| No | 330 (84) | 223 (86) | 107 (89) | |
| Yes | 63 (16) | 37 (14) | 26 (20) | |
| Abdominal surgery (n, %) | .542 | |||
| No | 323 (82) | 211 (81) | 112 (84) | |
| Yes | 70 (18) | 49 (29) | 21 (16) | |
| TURP (n, %) | .250 | |||
| No | 295 (75) | 190 (73) | 105 (79) | |
| Yes | 98 (25) | 70 (27) | 28 (21) | |
| tPSA (ng/ml) | 26.8 (13.5–65.3) | 25.3 (12.4–60.0) | 40.7 (16.2–91.9) | .017 |
| f/tPSA | .12 (.08–.17) | .11 (.07–.16) | .14 (.10–.19) | .007 |
| PSAD (ng/ml2) | .34 (.20–.65) | .36 (.20–.69) | .32 (.21–.64) | .747 |
| Prostate volume (ml) | 81 (55–125) | 74 (52–112) | 88 (66–135) | .078 |
| % of positive needles | .59 (.25–1.00) | .59 (.25–1.00) | 1.00 (.62–1.00) | <.001 |
| Gleason score (n, %) | <.001 | |||
| ≤3+3 | 88 (22) | 72 (28) | 16 (12) | |
| 3+4 | 57 (15) | 41 (16) | 16 (12) | |
| 4+3 | 97 (25) | 64 (25) | 33 (25) | |
| ≥4+4 | 151 (38) | 83 (32) | 68 (51) | |
| Risk category | <.001 | |||
| low-risk | 53 (13) | 51 (20) | 2 (2) | |
| intermediate-risk | 132 (34) | 99 (38) | 33 (27) | |
| High-risk | 208 (53) | 110 (42) | 98 (74) | |
| Pathological T stage (n, %) | <.001 | |||
| T2 | 278 (71) | 215 (83) | 63 (47) | |
| T3 | 89 (23) | 39 (15) | 50 (38) | |
| T4 | 26 (7) | 6 (2) | 20 (15) | |
| Nerve-sparing (n, %) | .018 | |||
| No | 366 (93) | 236 (91) | 130 (97) | |
| Yes | 27 (7) | 24 (9) | 4 (3) | |
Abbreviations: PSM, positive surgical; TURP, transurethral resection of the prostate; tPSA, total prostate-specific antigen; fPSA, free prostate-specific antigen; f/tPSA, fPSA / tPSA; PSAD, prostate-specific antigen density; NA, not applicable.
Univariate Logistic Regression Analysis of Preoperative Predictive Factors for Overall and Multifocal Positive Surgical Margin.
| Clinical Parameter | Surgical Margin | Solitary PSM vs Negative | Multifocal PSM vs Negative | |||
|---|---|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| |
| Age (years) | 1.00 (.97−1.02) | .737 | 1.00 (.96−1.03) | .853 | 1.00 (.96−1.05) | .884 |
| Smoking history (yes vs no) | 1.07 (.69−1.68) | .752 | .76 (.42−1.41) | .389 | 1.99 (1.07−3.70) | .030 |
| Drinking history (yes vs no) | 1.16 (.68−1.98) | .585 | .65 (.29−1.45) | .291 | 2.11 (1.06−4.19) | .033 |
| Hypertension (yes vs no) | 1.27 (.82−1.98) | .287 | 1.43 (.82−2.49) | .211 | 1.09 (.57−2.10) | .794 |
| Diabetes mellitus (yes vs no) | 1.46 (.84−2.54) | .176 | 1.59 (.80−3.16) | .183 | 1.36 (.61−3.03) | .457 |
| Abdominal surgery (yes vs no) | .81 (.46−1.41) | .454 | .94 (.47−1.89) | .861 | .49 (.18−1.30) | .151 |
| TURP (yes vs no) | .72 (.44−1.19) | .204 | .72 (.37−1.37) | .315 | .61 (.28−1.32) | .211 |
| tPSA (ng/ml) | 1.01 (1.00−1.02) | .011 | 1.00 (.99−1.01) | .589 | 1.01 (1.00−1.02) | .003 |
| f/tPSA | 1.59 (1.04−2.43) | .032 | 1.07 (.65−1.77) | .788 | 2.77 (1.44−5.34) | .002 |
| PSAD (ng/ml2) | .78 (.30−1.99) | .598 | .77 (.24−2.48) | .662 | 1.13 (.31−4.15) | .859 |
| Prostate volume (ml) | 1.00 (1.00−1.01) | .146 | 1.00 (.99−1.01) | .716 | 1.00 (.99−1.01) | .383 |
| % of positive needles | 6.85 (2.58−18.2) | <.001 | 2.72 (.91−8.13) | .073 | 38.6 (4.54−327) | <.001 |
| Gleason score (≤3+3 as reference) | ||||||
| 3+4 | 1.76 (.80−3.88) | .163 | 1.12 (.40−3.11) | .831 | 2.46 (.73−8.24) | .145 |
| 4+3 | 2.32 (1.17−4.61) | .016 | 1.74 (.76−3.99) | .191 | 2.70 (.90−8.08) | .076 |
| ≥4+4 | 3.69 (1.96−6.92) | <.001 | 2.52 (1.19−5.37) | .016 | 4.34 (1.58−11.9) | .004 |
| Nerve−spare (yes vs no) | .23 (.07−.77) | .017 | 1.06 (.54−2.09) | .858 | 1.54 (.65−3.61) | .325 |
Abbreviations: PSM, positive surgical margin; TURP, transurethral resection of the prostate; tPSA, total prostate-specific antigen; fPSA, free prostate-specific antigen; f/tPSA, fPSA / tPSA; PSAD, prostate-specific antigen density; ADT, androgen deprivation therapy; NA, not applicable.